Amylyx Pharmaceuticals, Inc.
AMLX
Kedudukan dalam Saham
#4492
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Harga Saham
$27.25
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$3.42B
Perubahan (1 hari)
3.45%
Perubahan (1 tahun)
77.29%
Negara
US
Perdagangan Amylyx Pharmaceuticals, Inc. (AMLX)
Kategori
Healthcare
Nisbah P/B bagi Amylyx Pharmaceuticals, Inc. (AMLX)
Nisbah P/B pada October 2026 TTM: 12.57
Menurut laporan kewangan dan harga saham terkini Amylyx Pharmaceuticals, Inc., nisbah P/B semasa (TTM) ialah 12.57. Pada akhir 2023, nisbah P/B syarikat ialah 2.28.
Sejarah nisbah P/B untuk Amylyx Pharmaceuticals, Inc. dari 2019 hingga 2026
Nisbah P/B pada akhir setiap tahun
| Tahun | Nisbah P/B | Ubah |
|---|---|---|
| 2026 (TTM) | 12.57 | 705.59% |
| 2024 | 1.56 | -31.54% |
| 2023 | 2.28 | -68.35% |
| 2022 | 7.22 | -204.32% |
| 2021 | -6.92 | -54.77% |
| 2020 | -15.29 | -62.00% |
| 2019 | -40.24 | 0.00% |
Nisbah P/B untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/B | Perbezaan Nisbah P/B | Negara |
|---|---|---|---|
| 6.251 | -50.26% |
US
|
|
| 13.2547 | 5.47% |
US
|
|
| 4.208 | -66.52% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -50.81% |
NL
|
